Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies

Autor: Charlie W. Lees, J. Jasper Deuring, Michael Chiorean, Marco Daperno, Gianluca Bonfanti, Rebecca Germino, Pritha Bhadra Brown, Irene Modesto, Roger A. Edwards

Publikováno v: Therapeutic Advances in Gastroenterology, Vol 14 (2021)

Introduction: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Outcome prediction based on early treatment response, along with clinical and laboratory variables, would be very useful for cli

Externí odkaz: https://doaj.org/article/b976d18342f54008bf2cc85a781bf595

The relationship between the reporting of euphoria events and early treatment responses to pregabalin: an exploratory post-hoc analysis

Autor: Pritha Bhadra Brown, Ed Whalen, Lloyd Knapp, Rainer Freynhagen, Stephan A. Schug, Bruce Parsons, Marie Ortiz

Publikováno v: Journal of Pain Research. 12:2577-2587

Background Euphoria is a complex, multifactorial problem that is reported as an adverse event in clinical trials of analgesics including pregabalin. The relationship between the reporting of euphoria events and pregabalin early treatment responses wa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c25498bd7e7d9ad801ad5344d7dbbc7e
https://doi.org/10.2147/jpr.s199203

sj-docx-1-tag-10.1177_17562848211054710 ��� Supplemental material for Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies

Autor: Lees, Charlie W., Deuring, J. Jasper, Chiorean, Michael, Daperno, Marco, Bonfanti, Gianluca, Germino, Rebecca, Brown, Pritha Bhadra, Modesto, Irene, Edwards, Roger A.

Supplemental material, sj-docx-1-tag-10.1177_17562848211054710 for Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies by Charlie W. Lees, J. Jasper Deuring, Michael Chiorean, Marco Daperno,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2fdd67f86ad3a2b8aa49e097d4d0b412

Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies

Autor: Irene Modesto, Roger A. Edwards, Marco Daperno, J Jasper Deuring, Gianluca Bonfanti, Rebecca Germino, Michael V. Chiorean, Pritha Bhadra Brown, Charlie W. Lees

Publikováno v: Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Lees, C W, Deuring, J J, Chiorean, M, Daperno, M, Bonfanti, G, Germino, R, Brown, P B, Modesto, I & Edwards, R A 2021, ' Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies ', Therapeutic Advances in Gastroenterology, vol. 14, pp. 17562848211054710 . https://doi.org/10.1177/17562848211054710

Introduction: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Outcome prediction based on early treatment response, along with clinical and laboratory variables, would be very useful for cli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa4c3741c6758396d8115fee93bbf94b
https://doi.org/10.1177/17562848211054710

A randomized study of the efficacy and safety of parecoxib for the treatment of pain following total knee arthroplasty in Korean patients

Autor: Hee Youn Choi, Margaret Noyes Essex, Pritha Bhadra Brown, Raymond Cheung

Publikováno v: Journal of Pain Research

Margaret Noyes Essex,1 Hee-Youn Choi,2 Pritha Bhadra Brown,1 Raymond Cheung1 1Pfizer Inc., New York, NY, USA; 2Pfizer Pharmaceutical Korea Ltd, Seoul, South Korea Purpose: Parecoxib is an injectable cyclooxygenase-2 inhibitor with proven postoperativ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78e77dce803010b134559272954664e5
https://www.dovepress.com/a-randomized-study-of-the-efficacy-and-safety-of-parecoxib-for-the-tre-peer-reviewed-article-JPR